<DOC>
	<DOCNO>NCT00253617</DOCNO>
	<brief_summary>RATIONALE : Stent placement may help reduce symptom cause tumor . Photodynamic therapy use drug , porfimer sodium , become active expose certain kind light . When drug active , tumor cell kill . This may effective treatment cholangiocarcinoma . It yet know whether stent placement photodynamic therapy use porfimer sodium effective stent placement alone treat cholangiocarcinoma . PURPOSE : This randomized phase III trial study stent placement photodynamic therapy use porfimer sodium see well work compare stent placement alone palliative treatment treat patient stage III stage IV cholangiocarcinoma remove surgery .</brief_summary>
	<brief_title>Stent Placement With Without Photodynamic Therapy Using Porfimer Sodium Palliative Treatment Treating Patients With Stage III Stage IV Cholangiocarcinoma That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare overall survival time patient unresectable Bismuth type III IV , stage III-IV cholangiocarcinoma treat double plastic endoprostheses insertion v without adjuvant photodynamic therapy use porfimer sodium palliative treatment . Secondary - Compare effect regimens cholestasis patient . - Compare 1-year survival rate patient treat regimen . - Compare health-related quality life patient treat regimen . OUTLINE : This randomize , control , open-label , multicenter study . Patients stratify accord participate center . Patients undergo endoscopic percutaneous drainage follow insertion bilateral plastic endoprostheses bile duct . Patients randomize 1 2 treatment arm . - Arm I : Patients receive porfimer sodium IV day 1 . Patients undergo endoscopic laser light therapy tumor site day 3 . - Arm II : Patients receive treatment . Quality life assess baseline week 2 , 13 , 26 , 39 , 52 , 65 . After completion study treatment , patient follow within 30-90 day . PROJECTED ACCRUAL : A total 120 patient ( 60 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Dihematoporphyrin Ether</mesh_term>
	<mesh_term>Trioxsalen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm cholangiocarcinoma Stage III IV disease Bismuth type III IV disease Tumor mass stricture cholangiogram CT scan Unresectable disease PATIENT CHARACTERISTICS : Performance status Karnofsky 30100 % Life expectancy Not specify Hematopoietic WBC ≥ 2,000/mm^3 Platelet count ≥ 50,000/mm^3 Hemoglobin ≥ 9.0 g/dL Hematocrit ≥ 27 % Hepatic PT INR ≤ 2 time upper limit normal ( correctable vitamin K ) No decompensated cirrhosis Renal Not specify Other Not pregnant Negative pregnancy test Fertile patient must use effective contraception No know porphyria hypersensitivity porphyrin No clinically significant acute chronic medial psychological illness would preclude study treatment No malignancy within past 5 year except carcinoma situ cervix basal cell skin cancer No concurrent untreated primary diagnosis anxiety depression PRIOR CONCURRENT THERAPY : Chemotherapy More 13 week since prior concurrent chemotherapy Radiotherapy More 13 week since prior concurrent brachytherapy radiotherapy Surgery No prior metal stent insertion No prior surgical resection cholangiocarcinoma Other No prior photodynamic therapy disease More 60 day since prior investigational drug No concurrent administration follow : Ursodiol Herbal product may increase bile flow , include follow : Andrographis paniculata Chelidonium majus L Curcumin L Cynara scolymus L ( artichoke ) Gentiana lutea Mentha x piperita ( peppermint ) Peumus boldus Mol Taraxacum officinale ( dandelion ) No administration follow within 7 day porfimer sodium injection : Supplements vitamins C , E , βcarotene Camellia sinensis ( green tea ) Silymarin EGb761</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>